LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results

J Bennouna ,M Benabdelghani,E Francois,N Kotecki ,P.-L Etienne ,J.-P Metges ,F El Hajbi ,E Samalin ,E Bogart ,F Ghiringhelli ,L Bedenne ,T Conroy ,P Michel ,L Dahan ,M.-P Galais ,S Delaine-Clisant ,G Piessen ,N Penel ,C Mariette ,A Adenis

doi:10.1093/annonc/mdw237.04

LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results

J Bennouna , M Benabdelghani + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdw237.04

Copy DOI

Journal: Annals of Oncology	Publication Date: Jun 1, 2016
License type: elsevier-specific: oa user license

Affiliation: Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Oscar Lambret, Centre Hospitalier Régional Universitaire de Brest, Institute of Cancer Research of Montpellier, Centre Georges François Leclerc, Maison des Sciences de l’Homme de Dijon, Institut de Cancérologie de Lorraine, Hôpital Charles-Nicolle, Hôpital de la Timone, Centre François Baclesse, Hôpital Claude Huriez

#Metastatic Squamous-cell Esophageal Cancer #Quality Of Life Results + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.